WD Rutherford LLC Has $517,000 Stock Holdings in IDEXX Laboratories, Inc. $IDXX

WD Rutherford LLC lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 964 shares of the company’s stock after selling 86 shares during the period. WD Rutherford LLC’s holdings in IDEXX Laboratories were worth $517,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. ORG Wealth Partners LLC acquired a new position in IDEXX Laboratories during the second quarter valued at approximately $273,000. Old Port Advisors grew its holdings in IDEXX Laboratories by 34.5% during the second quarter. Old Port Advisors now owns 5,361 shares of the company’s stock valued at $2,875,000 after purchasing an additional 1,376 shares during the last quarter. Patton Fund Management Inc. acquired a new position in IDEXX Laboratories during the second quarter valued at approximately $269,000. ST Germain D J Co. Inc. grew its holdings in IDEXX Laboratories by 158.5% during the second quarter. ST Germain D J Co. Inc. now owns 473 shares of the company’s stock valued at $254,000 after purchasing an additional 290 shares during the last quarter. Finally, CX Institutional boosted its position in shares of IDEXX Laboratories by 26.3% in the second quarter. CX Institutional now owns 648 shares of the company’s stock valued at $348,000 after acquiring an additional 135 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Up 2.3%

Shares of IDXX stock opened at $632.22 on Friday. The stock has a market cap of $50.58 billion, a P/E ratio of 52.64, a price-to-earnings-growth ratio of 4.09 and a beta of 1.56. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $688.12. The stock has a fifty day moving average price of $625.60 and a 200 day moving average price of $528.15. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, topping the consensus estimate of $3.28 by $0.35. The firm had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.IDEXX Laboratories’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same period last year, the business earned $2.44 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insider Transactions at IDEXX Laboratories

In related news, Director M Anne Szostak sold 2,187 shares of the firm’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total value of $1,415,710.71. Following the completion of the transaction, the director directly owned 262 shares of the company’s stock, valued at $169,600.46. This trade represents a 89.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 29,260 shares of the stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $631.98, for a total value of $18,491,734.80. Following the transaction, the chief executive officer owned 83,311 shares of the company’s stock, valued at $52,650,885.78. This represents a 25.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 54,057 shares of company stock valued at $34,293,468 over the last 90 days. Corporate insiders own 0.98% of the company’s stock.

Wall Street Analysts Forecast Growth

IDXX has been the subject of several research reports. Piper Sandler reissued a “neutral” rating and issued a $700.00 price objective (up from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. JPMorgan Chase & Co. increased their price objective on IDEXX Laboratories from $550.00 to $675.00 and gave the company an “overweight” rating in a research report on Monday, August 4th. Stifel Nicolaus set a $640.00 price objective on IDEXX Laboratories in a research report on Monday, August 4th. Jefferies Financial Group initiated coverage on IDEXX Laboratories in a research report on Tuesday, July 1st. They issued a “buy” rating and a $625.00 price objective for the company. Finally, Leerink Partners increased their price objective on IDEXX Laboratories from $580.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, July 17th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $649.44.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.